The Spread of Influenza A(H1N1)pdm09 in Victorian School Children in 2009: Implications for Revised Pandemic Planning

Fielding, James E.; Bergeri, Isabel; Higgins, Nasra; Kelly, Heath A.; Meagher, Julian; McBryde, Emma S.; Moran, Rodney; Hellard, Margaret E.; Lester, Rosemary A.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Victoria was the first state in Australia to experience community transmission of influenza A(H1N1)pdm09. We undertook a descriptive epidemiological analysis of the first 1,000 notified cases to describe the epidemic associated with school children and explore implications for school closure and antiviral distribution policy in revised pandemic plans. Methods: Records of the first 1,000 laboratory-confirmed cases of influenza A(H1N1)pdm09 notified to the Victorian Government Department of Health between 20 May and 5 June 2009 were extracted from the state’s notifiable infectious diseases database. Descriptive analyses were conducted on case demographics, symptoms, case treatment, prophylaxis of contacts and distribution of cases in schools. Results: Two-thirds of the first 1,000 cases were school-aged (5–17 years) with cases in 203 schools, particularly along the north and western peripheries of the metropolitan area. Cases in one school accounted for nearly 8% of all cases but the school was not closed until nine days after symptom onset of the first identified case. Amongst all cases, cough (85%) was the most commonly reported symptom followed by fever (68%) although this was significantly higher in primary school children (76%). The risk of hospitalisation was 2%. The median time between illness onset and notification of laboratory confirmation was four days, with only 10% of cases notified within two days of onset and thus eligible for oseltamivir treatment. Nearly 6,000 contacts were followed up for prophylaxis. Conclusions: With a generally mild clinical course and widespread transmission before its detection, limited and short-term school closures appeared to have minimal impact on influenza A(H1N1)pdm09 transmission. Antiviral treatment could rarely be delivered to cases within 48 hours of symptom onset. These scenarios and lessons learned from them need to be incorporated into revisions of pandemic plans.


Related Articles

  • Demographic Shift of Influenza A(H1N1)pdm09 during and after Pandemic, Rural India. Broor, Shobha; Sullender, Wayne; Fowler, Karen; Gupta, Vivek; Widdowson, Marc-Alain; Krishnan, Anand; Lal, Renu B. // Emerging Infectious Diseases;Sep2012, Vol. 18 Issue 9, p1472 

    Population-based active surveillance in India showed higher incidence rates for influenza A(H1N1)pdm09 among children during pandemic versus postpandemic periods (345 vs. 199/1,000 person-years), whereas adults had higher rates during postpandemic versus pandemic periods (131 vs. 69/1,000...

  • Oseltamivir use in infants under one year of age: are there still unanswered questions? Kara, Ateş; Karadağ-Öncel, Eda; Özkaya-Parlakay, Aslınur; Korukluoğlu, Gülay; Bağdat, Arzu; Çelik, Melda; Ceyhan, Mehmet; Cengiz, Ali Bülent // Turkish Journal of Pediatrics;Jan/Feb2012, Vol. 54 Issue 1, p25 

    The influenza A (H1N1) virus responsible for the 2009 pandemic follows a more severe course in children, thus increasing the need for hospitalization. On the other hand, during the first weeks of the pandemic, use of oseltamivir (Tamiflu®) in children was restricted, and it was not yet...

  • Five easy steps to bird flu pandemic. MacKenzie, Debora // New Scientist;9/24/2011, Vol. 211 Issue 2831, p14 

    The article looks at genetic mutations to the avian flu virus H5N1 that would allow it to spread more easily among mammals, possibly inciting a pandemic. H5N1 research done by Ron Fouchier and colleagues at the Erasmus Medical Centre in Rotterdam, the Netherlands that suggests that as few as...

  • Oseltamivir effective when administered early for H5N1.  // Infectious Disease News;Dec2012, Vol. 25 Issue 12, p39 

    The article discusses a study on the effectiveness of oseltamivir in people with influenza virus A subtype H5N1.

  • The antigenic property of the H5N1 avian influenza viruses isolated in central China. Wei Zou; Jianjiang Ke; Jiping Zhu; Hongbo Zhou; Meilin Jin // Virology Journal;2012, Vol. 9 Issue 1, p148 

    Background: Three influenza pandemics outbroke in the last century accompanied the viral antigen shift and drift, resulting in the change of antigenic property and the low cross protective ability of the existed antibody to the newly emerged pandemic virus, and eventually the death of millions...

  • Human H5N1 influenza infections in Cambodia 2005-2011: case series and cost-of-illness. Humphries-Waa, Karen; Drake, Tom; Huszar, Anthony; Liverani, Marco; Borin, Khieu; Touch, Sok; Srey, Teng; Coker, Richard // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background: Southeast Asia has been identified as a potential epicentre of emerging diseases with pandemic capacity, including highly pathogenic influenza. Cambodia in particular has the potential for high rates of avoidable deaths from pandemic influenza due to large gaps in health system...

  • No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix Vaccination Campaign in Finland. Melén, Krister; Partinen, Markku; Tynell, Janne; Sillanpää, Maarit; Himanen, Sari-Leena; Saarenpää-Heikkilä, Outi; Hublin, Christer; Olsen, Päivi; Ilonen, Jorma; Nohynek, Hanna; Syrjänen, Ritva; Kilpi, Terhi; Vuorela, Arja; Kirjavainen, Turkka; Vaarala, Outi; Julkunen, Ilkka // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: Narcolepsy cataplexy syndrome, characterised by excessive daytime sleepiness and cataplexy, is strongly associated with a genetic marker, human leukocyte antigen (HLA) DQB1*06:02. A sudden increase in the incidence of childhood narcolepsy was observed after vaccination with...

  • Insight into the Oseltamivir Resistance R292K Mutation in H5N1 Influenza Virus: A Molecular Docking and Molecular Dynamics Approach. Karthick, V.; Ramanathan, K. // Cell Biochemistry & Biophysics;Mar2014, Vol. 68 Issue 2, p291 

    H5N1 is a subtype of the influenza A virus that can cause disease in humans and many other animal species. Oseltamivir (Tamiflu) is a potent and selective antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase (NA), a flu protein responsible for the...

  • Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal. Ndongo Dia; Niang, Mbayame N.; Diadhiou, Saadiya A.; Goudiaby, Déborah G.; Faye, Abdourahmane; Kiori, Davy; Bâ, Mady; Michel, Rémy; Diop, Ousmane M. // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Among Influenza neuraminidase inhibitors (NAIs), oseltamivir corresponds to the most widely used agent to treat influenza disease. However since 2001, several cases of resistance to NAIs have been reported for circulating seasonal A(H1N1) Influenza viruses. A direct resistance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics